You are here

P&T January 2013

Features

Less Hospital Access to Outside Vendors and More Visits From State Pharmacy Boards

To avoid more fatalities and cases of fungal meningitis, as occurred from contaminated steroid products made at the New England Compounding Center, hospitals and their pharmacy directors must stay abreast of future changes in state and federal laws regarding compounding.

The authors review the challenges in diagnosis; the roles of stress, neurotransmitters, and biological factors; cognitive–behavior therapy; and pharmacological and nonpharmacological strategies in patients with anxiety.

An Update on Rivaroxaban (Xarelto)

Novel anticoagulants represent promising alternatives to the traditional anticoagulants for VTE prophylaxis following hip and knee replacement surgery. Preliminary analyses for rivaroxaban suggest that it may be cost-effective and cost-saving in these patients.

Departments